A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC)

  • Cancer
  • Breast Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • bei-jing-shi
  • chang-chun-shi
  • chang-zhou-shi
  • Cheng Du Shi
  • fu-zhou-shi
  • guang-zhou-shi
  • hang-zhou-shi
  • Harbin
  • nan-jing-shi
  • shang-hai-shi
  • shen-yang-shi
  • Shenyang
Trial Identifier:

NCT02896855 YO29296

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial in China will evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel compared with placebo + trastuzumab + docetaxel in participants with previously untreated HER2-positive metastatic breast cancer.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02896855,YO29296 Trial Identifier
      Docetaxel, Pertuzumab, Placebo, Trastuzumab Treatments
      Breast Cancer Condition
      Official Title

      A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab+Herceptin+Docetaxel Versus Placebo+Herceptin+Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease that is suitable for chemotherapy
      • HER2-positive metastatic breast cancer (MBC)
      • Left ventricular ejection fraction (LVEF) greater than or equal to (>=) 55 percent (%) at baseline (within 42 days of randomization)
      • Eastern Cooperative Oncology Group Performance Status of 0 or 1
      • Women of childbearing potential and men should agree to use an effective form of contraception and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment (trastuzumab and/or pertuzumab)
      Exclusion Criteria
      • History of anti-cancer therapy for MBC (with the exception of one prior hormonal regimen for MBC)
      • History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the neoadjuvant or adjuvant setting
      • History of systemic breast cancer treatment in the neo-adjuvant or adjuvant setting with a disease-free interval from completion of the systemic treatment (excluding hormonal therapy) to metastatic diagnosis of less than (<) 12 months
      • History of persistent Grade >= 2 hematologic toxicity resulting from previous adjuvant therapy
      • Grade >= 3 peripheral neuropathy at randomization
      • History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or non-melanoma skin carcinoma that has been previously treated with curative intent
      • Current clinical or radiographic evidence of central nervous system (CNS) metastases
      • History of exposure to cumulative doses of anthracyclines
      • Current uncontrolled hypertension or unstable angina
      • History of congestive heart failure (CHF) of any New York Heart Association (NYHA) classification, or serious cardiac arrhythmia requiring treatment
      • History of myocardial infarction within 6 months of randomization
      • History of LVEF decrease to < 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy
      • Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy
      • Inadequate organ function within 28 days prior to randomization
      • Current severe, uncontrolled systemic disease
      • Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment
      • Pregnant or lactating women
      • History of receiving any investigational treatment within 28 days of randomization
      • Current known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or active hepatitis B virus (HBV)
      • Receipt of intravenous (IV) antibiotics for infection within 14 days of randomization
      • Current chronic daily treatment with corticosteroids (excluding inhaled steroids)
      • Known hypersensitivity to any of the protocol-specified study treatments
      • Concurrent participation in an interventional or noninterventional study

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now